HLCS News

Helicos BioSciencies, which is developing genetic analysis technologies for research and drug discovery uses, priced its IPO of 5.4 million shares at $9 on Thursday morning. The offer price represented a 36% discount to the midpoint of its originally proposed...read more

Helicos BioSciences, which is developing genetic analysis technologies for research and drug discovery uses, lowered the anticipated price of its IPO again on Thursday. The company announced in its SEC filing that it anticipated a $9.00 price tag on its shares. ...read more

Helicos BioSciences, which is developing genetic analysis technologies for research and drug discovery uses, lowered its anticipated price range Wednesday. The revised price range is $10-$11, 25% below the midpoint of the original $13-$15 price range. UBS is...read more

Helicos BioSciences, a developer of genetic analysis technologies for the research, drug discovery and clinical diagnostics markets, announced the terms of its IPO Monday. The company plans to offer 5.4 million shares at a price between $13.00 and $15.00. UBS...read more